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STO (p<0.001, all). Combination of these ﬁndings could distinguish
CTO from STO (c-statistics¼0.88 (95% CI¼0.94–0.90),
sensitivity¼83%, speciﬁcity¼77%, positive predictive value (PPV)¼
55%, negative predictive value (NPV)¼93%, p<0.001). Percutaneous
coronary intervention (PCI) was attempted in 342 arteries and was
successful in 279 arteries (82%). CT ﬁndings could predict the un-
successful PCI (c-statistics¼0.70 (0.65–0.75), sensitivity¼63%, specif-
icity¼73%, PPV¼91%, NPV¼31%, p<0.001).
CONCLUSIONS Non-invasive coronary CT angiography could discern
chronic total occlusion from subtotal occlusion, and also could predict
the success of attempted PCI.
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BACKGROUND Previous studies have shown that high and low
platelet reactivity (HPR and LPR respectively) are associated with
adverse events following percutaneous coronary intervention (PCI),
however, therapy windows were not consistent in different studies.
We aimed to determine the optimal cutoff value of platelet reactivity
to prevent major adverse events (MACE) and bleeding in eastern Asian
PCI patients.
METHODS Consecutive 6266 non-emergent PCI patients with aspirin
and clopidogrel therapy were enrolled prospectively in the single-
center, large-volume investigation from January to December 2013.
Platelet reactivity (ADP-induced platelet-ﬁbrin clot strength
[MAADP]) was determined by thrombelastography. MACE and
Bleeding Academic Research Consortium (BARC) classiﬁcation2
bleeding were assessed between different categories of platelet reac-
tivity and Syntax Score (SS).
RESULTS Overall, 475 MACE and 152 major bleeding (BARC grade2)
events were recorded during one year follow-up. With receiver
operating characteristic (ROC) curve, we determined the cutoff values
of MAADP for MACE and major bleeding (45 mm and 34mm, respec-
tively). Then, patients were classiﬁed according to MAADP (>45 mm,
34–45 mm, and <34 mm) and we evaluated the impact of platelet
reactivity on MACE and major bleeding in different Syntax Score
subgroups (SS<15 and SS15) with multivariable Cox survival anal-
ysis. In low SS group, MAADP>45 mm was the predictor of MACE (HR:
2.3; 95%CI: 1.6-5.9), but MAADP<34 mm did not show signiﬁcant
predicting value for major bleeding (HR: 1.3; 95%CI: 0.4-8.1). In high
SS group, MAADP>45 mm was still the predictor of MACE (HR: 2.6;
95%CI: 1.3-6.3), while MAADP<34 mm show signiﬁcant impact on
major bleeding (HR: 1.8; 95%CI: 1.2-4.7).
CONCLUSIONS Platelet reactivity measured by thrombelastography
could predict MACE and major bleeding in elective PCI patients,
especially in those with high SS. Therapy window of anti-platelet
drugs is narrow in eastern Asian population and further studies on
tailored treatment of high-risk patients are needed.
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BACKGROUND Drug-eluting stents (DES) reduce angiographic reste-
nosis and enhance event-free survival compared with bare-metalstents after implantation in coronary arteries. Limitations of current
DES remain stent thrombosis and neo-atherosclerosis related to
impaired healing, and repeat revascularization due to (late-) in-
stent-restenosis. Endothelial repair can be substantially enhanced
by CD34þ endothelial progenitor cells. The Combo stent combines a
CD34þ antibody layer to attract endothelial progenitor cells, and
thus promotes stent healing, with the abluminal release of sirolimus
to prevent neointima formation and restenosis. The aim of this
registry is to evaluate the long term safety and performance of the
abluminal sirolimus coated bio-engineered stent in routine clinical
practice.
METHODS The multicenter, prospective, clinical outcomes after
deployment of the abluminal sirolimus coated bio-engineered stent
post market registry, the REMEDEE Registry, is an international
registry to evaluate outcomes in an all-comers population of patients
undergoing percutaneous coronary intervention with (attempted)
Combo stent placement in the setting of routine clinical care. Base-
line demographic, clinical, and angiographic data, as well as follow-
up data up to ﬁve years will be obtained. Clinical endpoints are
deﬁned as a composite of cardiac death, non-fatal myocardial
infarction (MI) not clearly attributable to a non-target vessel, or
target lesion revascularization (TLR) (percutaneous or by coronary
artery bypass grafting (CABG)) in consecutive patients undergoing
percutaneous coronary intervention with (attempted) Combo stent
placement. All events will be adjudicated by an independent Clinical
Events Committee. Cumulative event rates are estimated by a
Kaplan-Meier model.
RESULTS A total of 1000 patients were included in 9 European sites
between June 2013 and March 2014, of which 30.4% patients pre-
senting with acute coronary syndrome (ACS) (17.8% ST-segment
elevation myocardial infarction). Mean age was 6511 years, 73.9% of
patients are male. 184 (18.4%) patients are diabetic, 25.3% of patients
have had a previous myocardial infarction, 6.8% had previous CABG.
The primary endpoint of one year target lesion failure will be available
at the TCT conference 2015.
CONCLUSIONS This is the ﬁrst multicenter, prospective, non-inter-
ventional trial evaluating the long term clinical outcomes of patients
treated with a Combo stent.
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BACKGROUND The incidence, predictors, and prognostic impact of
post-discharge bleeding (PDB) after percutaneous coronary interven-
tion (PCI) with drug-eluting stent (DES) implantation are unclear. This
study sought to characterize the determinants and consequences of
PDB after PCI.
METHODS The incidence and predictors of clinically relevant
bleeding events occurring within 2 years following hospital
discharge were assessed from the prospective Assessment of Dual
Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) study.
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was estimated by time-adjusted Cox proportional hazards
regression.
RESULTS Among 8,582 “all-comers” patients who underwent suc-
cessful PCI with DES in the ADAPT-DES study, PDB occurred in 535/
8,577 hospital survivors (6.2%) at a median time of 300 days (inter-
quartile range: 130 to 509 days) after hospital discharge. Gastroin-
testinal bleeding (61.7%) was the most frequent source of PDB.
Predictors of PDB included older age, lower baseline hemoglobin,
lower platelet reactivity on clopidogrel, and use of chronic oral anti-
coagulation therapy. PDB was associated with higher crude rates of
all-cause mortality (13.0% vs. 3.2%; p<0.0001; Figure). Following
multivariable adjustment, PDB was strongly associated with 2-year
mortality (HR: 5.03; 95% CI: 3.29–7.66; p<0.0001), with an effect
size greater than that of post-discharge myocardial infarction (PDMI)
(HR: 1.92; 95% CI: 1.18–3.12; p¼0.009).
CONCLUSIONS Following successful PCI with DES in an unrestricted
patient population, PDB is not uncommon, and has a strong rela-
tionship with subsequent all-cause mortality, greater that that asso-
ciated with PDMI. Efforts to reduce PDB may further improve
prognosis after successful DES implantation.
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BACKGROUND The PE Plus Post-Approval Study (PE Plus PAS) was
designed to examine long-term outcomes among patients treated
with advanced generation, everolimus-eluting, platinum chromium
PROMUS Element stents (Boston Scientiﬁc, Marlborough, MA) in
unselected patients treated in routine practice. This is the ﬁrst
report of 2-year results from this large multicenter post-approval
study.
METHODS PE Plus PAS was a prospective, open-label, multicenter
observational study enrolling 2684 patients at 52 sites in the US.
Follow-up was at 30 days, 6 months, and 1 year, and will continue
annually through 5 years. The primary endpoint was 12-monthcardiac death or myocardial infarction (CD/MI) in ‘PLATINUM-like’
patients who received PROMUS Element Plus in PE Plus PAS, PE
PROVE and patients from the PLATINUM Workhorse/Small Vessel
trials compared to a performance goal (3.2%) derived from out-
comes in SPIRIT IV and the PLATINUM trial. The PLATINUM-like
patient cohort was deﬁned as all patients that met the criteria for
enrollment in the PLATINUM trial. A Clinical Events Committee
adjudicated major adverse cardiac events and their relatedness to
the study stent.
RESULTS In the PE Plus PAS, 30% of patients were female, mean
age was 64 years, 37% had medically treated diabetes, and more
than three-quarters were treated for hyperlipidemia and hyperten-
sion. At baseline, mean lesion length was 1710 mm and mean
reference vessel diameter was 2.90.5 mm (in 3595 treated lesions).
PLATINUM-like patients accounted for 29% of the overall PE Plus
PAS patient population. For the primary endpoint, 12-month CD/MI
in PLATINUM-like patients was 1.8% (33/1855) with a upper 1-sided
95% conﬁdence interval of 2.3%, which was signiﬁcantly less than
the prespeciﬁed performance goal of 3.2% (Pnoninferiority<0.001).
In the overall PE Plus population, 12-month major adverse cardiac
events were low.
CONCLUSIONS The 2-year results from the PE Plus PAS will be
available for presentation for the ﬁrst time at TCT 2015 and will show
favorable performance and safety for the PROMUS Element Plus
everolimus-eluting stent at 2 years in an unselected patient
population.
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BACKGROUND The beneﬁt on prognosis after successful recanaliza-
tion of chronic total occlusion (CTO) lesions is uncertain.
METHODS A total of 1173 consecutive patients (mean age 60 years,
82.7% men) with CTOs of native coronary vessels in which per-
cutaneous coronary intervention (PCI) was attempted was enrolled
from March 2003 and May 2014. All successful procedures
(1004 patients, 85.6%) were performed by drug-eluting stent
implantation.
RESULTS During a median of 4.6-year of follow-up, the cumulative
incidence of all-cause death was not signiﬁcantly different between
the successful and unsuccessful CTO-PCI (8.0% vs. 7.1%, P ¼ 0.83).
The cumulative rate of target vessel revascularization (TVR) and
coronary artery bypass grafting (CABG) was remarkably less in
patients with successful PCI compared with those with unsuc-
cessful PCI (TVR; 4.4% vs. 20.9%, P < 0.001, CABG; 0.4% vs.
16.7%, P < 0.001). The adjusted risks of all-cause death (hazard
ratio [HR] 1.19, 95% conﬁdence interval [CI] 0.59 – 2.43, P ¼ 0.62)
and the composite of death or myocardial infarction ([MI], HR 1.06,
95% CI 0.56 – 2.03, P ¼ 0.96) remained comparable between
groups, whereas the adjusted risk of TVR and CABG was signiﬁ-
cantly higher in patients with unsuccessful CTO PCI. Among 879
subjects who eventually had a complete revascularization state for
the non-CTO vessels, the risks of death or the composite of death
or MI were not different between patients who further underwent
successful recanalization of the remaining CTO and those who
did not. This ﬁnding was consistent regardless of whether the
patient had a multi-vessel disease including CTO or only had a
single CTO.
CONCLUSIONS Successful CTO-PCI compared with unsuccessful PCI
was not associated with lesser risk for 4.6-year mortality, but was
associated with signiﬁcantly less subsequent CABG.
